AR066292A1 - Tratamiento para la degeneracion macular relacionada con el envejecimiento utilizando inhibidores de factor d complementario - Google Patents
Tratamiento para la degeneracion macular relacionada con el envejecimiento utilizando inhibidores de factor d complementarioInfo
- Publication number
- AR066292A1 AR066292A1 ARP080101742A ARP080101742A AR066292A1 AR 066292 A1 AR066292 A1 AR 066292A1 AR P080101742 A ARP080101742 A AR P080101742A AR P080101742 A ARP080101742 A AR P080101742A AR 066292 A1 AR066292 A1 AR 066292A1
- Authority
- AR
- Argentina
- Prior art keywords
- risk
- amd
- patient
- complementary
- complementary factor
- Prior art date
Links
- 230000000295 complement effect Effects 0.000 title abstract 7
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 230000032683 aging Effects 0.000 title abstract 2
- 208000002780 macular degeneration Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 abstract 5
- 108010053085 Complement Factor H Proteins 0.000 abstract 2
- 230000018109 developmental process Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Métodos para identificar un paciente en riesgo de desarrollar AMD identificando la presencia del polimorfismo Y402H u otras variantes de riesgo del gen del factor H complementario. La presente además proporciona métodos para tratar personas quetienen AMD o que se encuentran en riesgo de desarrollar AMD como resultado de tener el polimorfismo Y402H u otras variantes de riesgo en el gen del factor H complementario. Reivindicacion 1: Un método para inhibir la pérdida de la acuidad visualasociada con la degeneracion macular relacionada con el envejecimiento (AMD) en un paciente que tiene AMD o está en riesgo de desarrollar AMD debido a la presencia de una variante de riesgo en un gen familiar complementario, método que comprende: a)identificar dicha variante de riesgo en dicho paciente por medio de i) la obtencion de una muestra de tejido de dicho paciente; y ii) el estudio de dicha muestra de tejido para buscar la presencia de dicha variante de riesgo, donde la presencia dedicha variante de riesgo indica un riesgo aumentado que produce el desarrollo de AMD o el avance de AMD-seco a AMD-humedo; b) administrar al paciente identificado en el paso (a) anterior como que posee dicha variante de riesgo, una cantidadterapéuticamente efectiva de una composicion que contiene un inhibidor de factor D complementario. Reivindicacion 7: El método de la reivindicacion 6, donde la composicion se realiza por medio de un dispositivo de administracion sostenidaimplantado en forma intravítrea. Reivindicacion 8: Una composicion oftalmologica que contiene un inhibidor del factor D complementario en un portador farmacéuticamente aceptable. Reivindicacion 9: La composicion de la reivindicacion 8, donde elinhibidor del factor D complementario es BCX-1 470.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91487707P | 2007-04-30 | 2007-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066292A1 true AR066292A1 (es) | 2009-08-12 |
Family
ID=39586997
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101742A AR066292A1 (es) | 2007-04-30 | 2008-04-24 | Tratamiento para la degeneracion macular relacionada con el envejecimiento utilizando inhibidores de factor d complementario |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20080269318A1 (es) |
| EP (1) | EP2139471A2 (es) |
| JP (1) | JP2010526074A (es) |
| KR (1) | KR20100014486A (es) |
| CN (1) | CN101674824A (es) |
| AR (1) | AR066292A1 (es) |
| AU (1) | AU2008248043A1 (es) |
| BR (1) | BRPI0811007A2 (es) |
| CA (1) | CA2680833A1 (es) |
| CL (1) | CL2008001259A1 (es) |
| MX (1) | MX2009009738A (es) |
| RU (1) | RU2009144142A (es) |
| TW (1) | TW200900056A (es) |
| UY (1) | UY31061A1 (es) |
| WO (1) | WO2008137236A2 (es) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2316394B1 (en) | 2001-06-12 | 2016-11-23 | The Johns Hopkins University | Reservoir device for intraocular drug delivery |
| US8623395B2 (en) | 2010-01-29 | 2014-01-07 | Forsight Vision4, Inc. | Implantable therapeutic device |
| CA3045436C (en) | 2009-01-29 | 2025-10-07 | Forsight Vision4 Inc | Posterior segment drug delivery |
| US10166142B2 (en) | 2010-01-29 | 2019-01-01 | Forsight Vision4, Inc. | Small molecule delivery with implantable therapeutic device |
| HUE057267T2 (hu) * | 2010-08-05 | 2022-05-28 | Forsight Vision4 Inc | Berendezés szem kezelésére |
| HUE054113T2 (hu) | 2010-08-05 | 2021-08-30 | Forsight Vision4 Inc | Injekciós készülék gyógyszerbejuttatáshoz |
| EP2640360A2 (en) | 2010-11-19 | 2013-09-25 | Forsight Vision4, Inc. | Therapeutic agent formulations for implanted devices |
| RU2495650C1 (ru) * | 2012-02-29 | 2013-10-20 | Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации | Трехкомпонентный комплекс для клеточной терапии в офтальмологии |
| RU2485922C1 (ru) * | 2012-03-28 | 2013-06-27 | Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации | Способ лечения "сухой" формы возрастной макулярной дегенерации |
| RU2494711C1 (ru) * | 2012-05-18 | 2013-10-10 | Федеральное государственное бюджетное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения и социального развития Российской Федерации | Способ хирургического лечения прогрессирующей и осложненной миопии |
| AU2014236455B2 (en) | 2013-03-14 | 2018-07-12 | Forsight Vision4, Inc. | Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant |
| ES2972168T3 (es) | 2013-03-28 | 2024-06-11 | Forsight Vision4 Inc | Implante oftálmico para administración de sustancias terapéuticas |
| CR20160132A (es) * | 2013-08-12 | 2016-08-25 | Genentech Inc | Composiciones y método para tratar condiciones asociadas con el complemento |
| US11219552B2 (en) | 2013-09-06 | 2022-01-11 | The Regents Of The University Of Colorado, A Body Corporate | Intraocular filter device and methods of using same |
| EP3041524A4 (en) * | 2013-09-06 | 2017-06-14 | The Regents of the University of Colorado, a body corporate | Intraocular drug delivery and filter device and methods of using same |
| EP3054965B1 (en) * | 2013-10-07 | 2021-04-14 | Massachusetts Eye & Ear Infirmary | Anti-factor d antibody for use in preventing or reducing retinal detachment |
| DE102014107380A1 (de) | 2014-05-26 | 2015-11-26 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Verfahren zur Diagnose einer durch den alternativen Weg des Komplementsystems vermittelten Krankheit oder eines Risikos hierfür |
| KR101981532B1 (ko) | 2014-06-12 | 2019-09-02 | 라 파마슈티컬스 인코포레이티드 | 보체 활성의 조절 |
| CA2957548A1 (en) | 2014-08-08 | 2016-02-11 | Forsight Vision4, Inc. | Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof |
| PL3250230T3 (pl) | 2015-01-28 | 2022-02-14 | Ra Pharmaceuticals, Inc. | Modulatory aktywności dopełniacza |
| JP6912475B2 (ja) | 2015-11-20 | 2021-08-04 | フォーサイト・ビジョン フォー・インコーポレーテッドＦｏｒｓｉｇｈｔ Ｖｉｓｉｏｎ４， Ｉｎｃ． | 持続放出性薬物送達機器用の多孔質構造体 |
| RU2733720C2 (ru) | 2015-12-16 | 2020-10-06 | Ра Фармасьютикалз, Инк. | Модуляторы активности комплемента |
| CN108934169A (zh) * | 2016-01-20 | 2018-12-04 | 维特里萨医疗公司 | 用于抑制因子d的组合物和方法 |
| MX2019006527A (es) | 2016-12-07 | 2019-08-01 | Ra Pharmaceuticals Inc | Moduladores de la actividad del complemento. |
| WO2018136827A1 (en) | 2017-01-20 | 2018-07-26 | Vitrisa Therapeutics, Inc. | Stem-loop compositions and methods for inhibiting factor d |
| AU2018250695A1 (en) * | 2017-04-14 | 2019-11-07 | Kodiak Sciences Inc. | Complement factor D antagonist antibodies and conjugates thereof |
| TW201938184A (zh) | 2017-12-04 | 2019-10-01 | 美商Ｒａ製藥公司 | 補體活性之調節劑 |
| CN113543796A (zh) | 2019-03-08 | 2021-10-22 | Ra制药公司 | 齐鲁考普作为深层组织穿透性c5抑制剂 |
| US20230115176A1 (en) | 2019-03-29 | 2023-04-13 | Ra Pharmaceuticals, Inc. | Complement Modulators and Related Methods |
| US20220211799A1 (en) | 2019-04-24 | 2022-07-07 | Ra Pharmaceuticals, Inc. | Compositions and methods for modulating complement activity |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| BR112022022980A2 (pt) | 2020-05-12 | 2022-12-20 | Alexion Pharma Inc | Uso de inibidores de fator d de complemento sozinhos ou em combinação com anticorpos anti-c5 para tratamento de hemoglobinúria paroxística noturna |
| CN114686481B (zh) * | 2020-12-31 | 2023-08-15 | 北京键凯科技股份有限公司 | 一种抑制cfd表达的干扰rna及其制备方法和应用 |
| WO2025199107A1 (en) | 2024-03-19 | 2025-09-25 | Alexion Pharmaceuticals, Inc. | Risk evaluation and management strategy involving patient follow-ups relating to the use or discontinuation of a complement inhibitor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6653340B1 (en) * | 1997-06-03 | 2003-11-25 | Biocryst Pharmaceuticals, Inc. | Compounds useful in the complement, coagulat and kallikrein pathways and method for their preparation |
| US6413245B1 (en) * | 1999-10-21 | 2002-07-02 | Alcon Universal Ltd. | Sub-tenon drug delivery |
| EP2026073B1 (en) * | 2000-04-29 | 2016-03-30 | University Of Iowa Research Foundation | Diagnostics and therapeutics for macular degeneration-related disorders |
| EP2357257B1 (en) * | 2005-02-14 | 2019-07-31 | University of Iowa Research Foundation | Methods and reagents for treatment and diagnosis of age-related macular degeneration |
| EP2148691B1 (en) * | 2007-02-05 | 2015-05-20 | Apellis Pharmaceuticals, Inc. | Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system |
-
2008
- 2008-04-07 WO PCT/US2008/059556 patent/WO2008137236A2/en not_active Ceased
- 2008-04-07 AU AU2008248043A patent/AU2008248043A1/en not_active Abandoned
- 2008-04-07 KR KR1020097019578A patent/KR20100014486A/ko not_active Withdrawn
- 2008-04-07 MX MX2009009738A patent/MX2009009738A/es unknown
- 2008-04-07 EP EP08733143A patent/EP2139471A2/en not_active Withdrawn
- 2008-04-07 RU RU2009144142/15A patent/RU2009144142A/ru not_active Application Discontinuation
- 2008-04-07 JP JP2010506378A patent/JP2010526074A/ja not_active Withdrawn
- 2008-04-07 CA CA002680833A patent/CA2680833A1/en not_active Abandoned
- 2008-04-07 BR BRPI0811007-7A2A patent/BRPI0811007A2/pt not_active Application Discontinuation
- 2008-04-07 US US12/098,527 patent/US20080269318A1/en not_active Abandoned
- 2008-04-07 CN CN200880014124A patent/CN101674824A/zh active Pending
- 2008-04-24 AR ARP080101742A patent/AR066292A1/es unknown
- 2008-04-29 UY UY31061A patent/UY31061A1/es not_active Application Discontinuation
- 2008-04-29 TW TW097115670A patent/TW200900056A/zh unknown
- 2008-04-30 CL CL2008001259A patent/CL2008001259A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN101674824A (zh) | 2010-03-17 |
| JP2010526074A (ja) | 2010-07-29 |
| WO2008137236A2 (en) | 2008-11-13 |
| TW200900056A (en) | 2009-01-01 |
| US20080269318A1 (en) | 2008-10-30 |
| AU2008248043A1 (en) | 2008-11-13 |
| MX2009009738A (es) | 2009-09-24 |
| BRPI0811007A2 (pt) | 2015-01-27 |
| EP2139471A2 (en) | 2010-01-06 |
| RU2009144142A (ru) | 2011-06-10 |
| UY31061A1 (es) | 2008-10-31 |
| CL2008001259A1 (es) | 2009-01-02 |
| CA2680833A1 (en) | 2008-11-13 |
| KR20100014486A (ko) | 2010-02-10 |
| WO2008137236A3 (en) | 2009-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066292A1 (es) | Tratamiento para la degeneracion macular relacionada con el envejecimiento utilizando inhibidores de factor d complementario | |
| CO6561786A2 (es) | Terapia combinada para el tratamiento del cancer y ensayos de diagnostico relacionados | |
| BRPI0412909A (pt) | uso de rnai inibindo atividade de parp para a fabricação de um medicamento para o tratamento de cáncer | |
| BR112014010228A8 (pt) | inibidores de reciclagem de ácidos biliares para tratamento da doença de fígado e hipercolemia colestática | |
| NO20074999L (no) | Metode og preparat for behandling av perifere vaskulaere sykdommer | |
| BRPI0512220A (pt) | método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto | |
| BR112012006283A2 (pt) | formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte | |
| CO6270215A2 (es) | Trans-clomifeno para el sindrome metabolico | |
| WO2009021521A3 (en) | Use of gaboxadol for the manufacture of a medicament for treating stress-mediated depression | |
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| AR058749A1 (es) | Inhibidores de c3-convertasa para la prevencion y el tratamiento de la degeneracion macular relacionada con la edad en pacientes con variantes de riesgo de factor h de complemento | |
| Takeda et al. | Dimethyl fumarate suppresses metastasis and growth of melanoma cells by inhibiting the nuclear translocation of NF-κB | |
| UY31417A1 (es) | Una composicion farmacéutica y un proceso para dicha composicion farmacéutica | |
| WO2022047128A3 (en) | Method for treating complement mediated disorders caused by betacoronaviruses | |
| MX2010010799A (es) | Metodo de diagnostico, prevencion y tratamiento de las enfermedades de la masa osea. | |
| CL2025001153A1 (es) | Agentes de arni para inhibir la expresión de la proteína quinasa dm1 (dmpk) | |
| DE602005025347D1 (de) | Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten | |
| WO2009027703A3 (en) | Identifying organ damage | |
| MX2009009171A (es) | Administracion de acido 3,5-diyodotiropropionico para estimular perdida de peso y/o disminuir niveles de trigliceridos y/o para tratar sindrome metabolico. | |
| AR112070A1 (es) | Solución de infusión de levodopa | |
| Manuela et al. | Nicotine stimulation increases proliferation and matrix metalloproteinases-2 and-28 expression in human dental pulp cells | |
| EA200800397A1 (ru) | Композиции тизанидина и способы лечения с применением композиций | |
| DE602005020113D1 (de) | Verfahren zur behandlung von akuten rhinosinusitis | |
| PH12014502282A1 (en) | Method for treating hyperuricemia in patients with gout using halofenate or halofenic acid and an anti-inflammatory agent | |
| UY30557A1 (es) | Tratamiento y prevencion de la fibrosis intestinal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |